12-Chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide | 1014025-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 12-Chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
• 英文别名: 12-chloro-5H-quinolino[8,7-c][1,2]benzothiazine 6,6-dioxide
• CAS: 1014025-86-5
• 化学式: C₁₅H₉ClN₂O₂S
• 分子量: 316.768
• InChiKey: PBISRCZQPSAXLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-amino-N-(5-chloro-quinolin-8-yl)-benzenesulfonamide 在 亚硝酸特丁酯 作用下， 以 溶剂黄146 为溶剂， 反应 0.17h， 以73%的产率得到12-Chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide
  参考文献：
  名称：

  Convenient preparation of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors

  摘要：

  An efficient synthesis of a series of N-8-quinolinyl benzenesultarns as novel NF-kappa B inhibitors was described via diazotization-induced cyclization of easily accessible N-8-quinolinyl-2-aminobenzenesulfonamides. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.01.136

文献信息

• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• Sulfonaminoquinoline hepcidin antagonists
  申请人：Vifor (International) AG

  公开号：US09102688B2

  公开（公告）日：2015-08-11

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型的赫普西丁拮抗剂，包括它们的药物组合物和将其作为药物用于治疗铁代谢紊乱的用途，特别是铁缺乏症和贫血，特别是与慢性炎症性疾病相关的贫血。
• NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS
  申请人：Vifor (International) AG

  公开号：EP2675526B1

  公开（公告）日：2017-02-01
• US9102688B2
  申请人：——

  公开号：US9102688B2

  公开（公告）日：2015-08-11
• Convenient preparation of N-8-quinolinyl benzenesultams as novel NF-κB inhibitors
  作者：Yuli Xie、Gangli Gong、Yidong Liu、Shixian Deng、Alison Rinderspacher、Lars Branden、Donald W. Landry

  DOI：10.1016/j.tetlet.2008.01.136

  日期：2008.3

  An efficient synthesis of a series of N-8-quinolinyl benzenesultarns as novel NF-kappa B inhibitors was described via diazotization-induced cyclization of easily accessible N-8-quinolinyl-2-aminobenzenesulfonamides. (C) 2008 Elsevier Ltd. All rights reserved.